Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

1.

Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.

Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R.

J Clin Oncol. 2007 Aug 20;25(24):3680-7.

PMID:
17704416
[PubMed - indexed for MEDLINE]
2.

Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.

[No authors listed]

Drugs R D. 2006;7(3):197-201. Review.

PMID:
16752945
[PubMed - indexed for MEDLINE]
3.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

PMID:
21923608
[PubMed - indexed for MEDLINE]
4.

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.

Sims RB.

Vaccine. 2012 Jun 19;30(29):4394-7. doi: 10.1016/j.vaccine.2011.11.058. Epub 2011 Nov 26. Review.

PMID:
22122856
[PubMed - indexed for MEDLINE]
Free Article
5.

Therapeutic breast cancer vaccines: a new strategy for early-stage disease.

Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL.

BioDrugs. 2009;23(5):277-87. doi: 10.2165/11313490-000000000-00000. Review.

PMID:
19754218
[PubMed - indexed for MEDLINE]
6.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
7.

Vaccination against the HER-2/neu oncogenic protein.

Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML.

Endocr Relat Cancer. 2002 Mar;9(1):33-44. Review.

PMID:
11914181
[PubMed - indexed for MEDLINE]
Free Article
8.

Allogeneic breast cancer cell vaccines.

Dols A, Meijer SL, Smith JW 2nd, Fox BA, Urba WJ.

Clin Breast Cancer. 2003 Feb;3 Suppl 4:S173-80. Review.

PMID:
12620156
[PubMed - indexed for MEDLINE]
9.

[Anti-HER2 vaccines: The HER2 immunotargeting future?].

Ladjemi MZ, Jacot W, Pèlegrin A, Navarro-Teulon I.

Pathol Biol (Paris). 2011 Jun;59(3):173-82. doi: 10.1016/j.patbio.2009.04.002. Epub 2009 May 28. Review. French.

PMID:
19481373
[PubMed - indexed for MEDLINE]
10.

Advances in prostate cancer immunotherapies.

Basler M, Groettrup M.

Drugs Aging. 2007;24(3):197-221. Review.

PMID:
17362049
[PubMed - indexed for MEDLINE]
11.

Clinical trials of HER-2/neu-specific vaccines.

Murray JL, Przepiorka D, Ioannides CG.

Semin Oncol. 2000 Dec;27(6 Suppl 11):71-5; discussion 92-100. Review.

PMID:
11236031
[PubMed - indexed for MEDLINE]
12.

Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).

Harzstark AL, Small EJ.

Expert Opin Biol Ther. 2007 Aug;7(8):1275-80. Review.

PMID:
17696825
[PubMed - indexed for MEDLINE]
13.

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.

Jinushi M, Hodi FS, Dranoff G.

Immunol Rev. 2008 Apr;222:287-98. doi: 10.1111/j.1600-065X.2008.00618.x. Review.

PMID:
18364009
[PubMed - indexed for MEDLINE]
14.

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

Disis ML, Cheever MA.

Adv Cancer Res. 1997;71:343-71. Review.

PMID:
9111870
[PubMed - indexed for MEDLINE]
15.

Immunogenic HER-2/neu peptides as tumor vaccines.

Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M.

Cancer Immunol Immunother. 2006 Jan;55(1):85-95. Epub 2005 Oct 27. Review.

PMID:
15948002
[PubMed - indexed for MEDLINE]
16.

Sipuleucel-T: in metastatic castration-resistant prostate cancer.

Plosker GL.

Drugs. 2011 Jan 1;71(1):101-8. doi: 10.2165/11206840-000000000-00000. Review.

PMID:
21175243
[PubMed - indexed for MEDLINE]
17.

Antibodies and vaccines--hope or illusion?

Jäger D, Knuth A.

Breast. 2005 Dec;14(6):631-5. Epub 2005 Oct 20. Review.

PMID:
16242931
[PubMed - indexed for MEDLINE]
18.

Breast cancer immunotherapy.

Zhou J, Zhong Y.

Cell Mol Immunol. 2004 Aug;1(4):247-55. Review.

PMID:
16225767
[PubMed - indexed for MEDLINE]
Free Article
19.

HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.

Pupa SM, Tagliabue E, Ménard S, Anichini A.

J Cell Physiol. 2005 Oct;205(1):10-8. Review.

PMID:
15887236
[PubMed - indexed for MEDLINE]
20.

Cell technologies in immunotherapy of cancer.

Moiseyenko V, Imyanitov E, Danilova A, Danilov A, Baldueva I.

Adv Exp Med Biol. 2007;601:387-93. Review.

PMID:
17713028
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk